Neervannan Seshadri
SEC CIK 1827584 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | COO | 78.5K | — | $2.54M | 15 | 2023-03-15 | 2026-09-04 |
Most active insiders at TARS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Azamian Bobak R. | Pres, CEO, Board COB, Dir | — | $5.18M |
| 2 | LINK WILLIAM J PHD | Dir | — | $4.48M |
| 3 | Whitfield Dianne C. | CHRO | — | $2.69M |
| 4 | Lin Elizabeth Yeu | Chief Medical Off | — | $2.36M |
| 5 | Neervannan Seshadri | COO | — | $2.00M |
| 6 | Farrow Jeffrey S | See Remarks | — | $1.32M |
| 7 | Mottiwala Aziz | Chief Commercial Off | — | $892.5K |
| 8 | Wahl Bryan | GC | — | $850.4K |
| 9 | Goodrich Katherine | Dir | — | $183.4K |
| 10 | Goldberg Andrew D. | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-09 16:12 | 2026-09-04 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $85.00 | -4,564 | 78.5K | -5% | -$387.9K |
| 2026-03-24 | 2026-03-20 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $66.75 | -2,989 | 82.8K | -3% | -$199.5K | |
| M | 2026-03-19 | 2026-03-17+ | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $68.21 | -11.3K | 94.0K | -11% | -$772.4K |
| D | 2026-03-17 | 2026-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | M - OptEx | — | +26.3K | 97.1K | +37% | — |
| 2026-03-05 | 2026-03-04 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $76.67 | -8,366 | 70.8K | -11% | -$641.4K | |
| I | 2025-12-18 | 2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | G - Gift | $0.00 | +475 | 475 | New | $0 |
| 2025-12-18 | 2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | G - Gift | $0.00 | -950 | 79.2K | -1% | $0 | |
| M | 2025-03-20 | 2025-03-18+ | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $47.89 | -7,583 | 79.7K | -9% | -$363.1K |
| D | 2025-03-18 | 2025-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | M - OptEx | — | +21.3K | 87.3K | +32% | — |
| D | 2024-03-19 | 2024-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | M - OptEx | — | +13.2K | 69.6K | +23% | — |
| D | 2024-03-19 | 2024-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale+OE | $30.60 | -4,879 | 64.8K | -7% | -$149.3K |
| M | 2023-03-23 | 2023-03-21+ | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $12.55 | -1,141 | 55.5K | -2% | -$14.3K |
| M | 2023-03-21 | 2023-03-17+ | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $12.94 | -740 | 56.2K | -1% | -$9,573 |
| D | 2023-03-17 | 2023-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | M - OptEx | — | +5,097 | 56.9K | +10% | — |
| D | 2023-03-17 | 2023-03-16 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale+OE | $13.43 | -357 | 56.6K | -0.6% | -$4,795 |
Purchase Sale Sale after option exercise All abbreviations